Pulmonary complications during granulocyte transfusions: incidence and clinical features.
The use of granulocyte transfusions in profoundly neutropenic patients has increased markedly in recent years. Whenever a pulmonary infiltrate develops during the course of these transfusions, the question arises as to what role the transfusions are playing and whether the transfusions should be discontinued to prevent pulmonary deterioration. We have analyzed our recent experience of 593 granulocyte transfusions in 93 patients. 18 patients (19%) developed respiratory compromise or pulmonary infiltrates at some time during the course of granulocyte transfusion. 6 of the 18 cases were reactions to the granulocytes while the remainder were due to fluid overload or other causes. The risk of pulmonary complications did not correlate with the development of cytotoxic leukocyte antibodies, length of transfusion, or concomitant use of Amphotericin. They appeared to be more common in patients with active sepsis. Acute life-threatening pulmonary reactions were rare. Patients receiving granulocyte transfusions should be monitored carefully for pulmonary infiltrates, but other cases should be sought before the transfusions are discontinued.
D000208:Acute Disease; D000371:Agglutination; D000666:Amphotericin B / Q000627:therapeutic use; D001424:Bacterial Infections / Q000150:complications; D001998:Bronchopulmonary Sequestration / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D006098:Granulocytes / Q000637:transplantation*; D006801:Humans; D007223:Infant; D008171:Lung Diseases / Q000209:etiology*; D012128:Respiratory Distress Syndrome / Q000209:etiology; D065227:Transfusion Reaction
D000666:Amphotericin B